Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Sintilimab/Chemo Improves OS in Frontline Advanced or Metastatic Gastric or GEJ Adenocarcinoma

August 16th 2021

Sintilimab plus oxaliplatin/capecitabine significantly improved overall survival over chemotherapy alone when used as a first-line treatment in patients with unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.

Current Role of Locoregional Therapy for Early Stage HCC

August 13th 2021

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.

Diagnosing Early-Stage HCC via Biopsy

August 13th 2021

A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.

Dr. Harris on the Adoption of Immunotherapy in Advanced HCC

August 10th 2021

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.

MSI-H Metastatic CRC: Chemo Vs I-O Debated

August 10th 2021

Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.

MSI-H Metastatic CRC: Frontline Immunotherapy

August 10th 2021

Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.

Dr. Wang on the Rationale for Viral Hepatitis Screening to Prevent HCC

August 9th 2021

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Global Real-World Data Establish TheraSphere Y-90 as Optimal Choice for HCC

August 6th 2021

TheraSphere Y-90 glass microspheres offer a precision medicine technique aimed at delivering high-dose radiation directly to tumors.

Diagnostic Testing for Early Stage HCC

August 6th 2021

The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.

Screening for Early Stage HCC

August 6th 2021

A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.

Metastatic CRC: Frontline Therapy With EGFR Inhibitors

August 3rd 2021

Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.

MSS Metastatic CRC: First-Line Treatment Selection

August 3rd 2021

Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.

Emerging Agents and Biomarkers in Gastric and GEJ Cancers 

August 2nd 2021

Daniel Catenacci, MD, and Sam Klempner, MD, conclude their discussion by examining emerging agents and biomarkers for the management of advanced gastric and esophagogastric junction cancers.

Sequencing After Progression on IO-Based Therapy for mGC

August 2nd 2021

Experts in the management of gastric cancer discuss best practices for monitoring signs and symptoms of disease progression and explore factors to consider when switching therapies in later lines of treatment.

Frontline Therapy for Metastatic PD-L1–, HER2+ Gastric Cancer

August 2nd 2021

Gastric cancer specialists emphasize the importance of communication and education when selecting first-line treatment for patients with PD-L1-negative, HER2-positive disease.

Adjuvant Nivolumab Approved in Europe for Select Esophageal or GEJ Cancers

July 30th 2021

The European Commission has approved nivolumab for use as an adjuvant treatment in adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiation.

Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up

July 29th 2021

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

Infigratinib Opens Up Options for Patients With FGFR2-Mutant Cholangiocarcinoma

July 29th 2021

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

Anti-EGFR/Chemo Combos Allow for Tailored Approach in mCRC

July 28th 2021

Ardaman Shergill, MD, discussed the use of EGFR inhibitors in metastatic colorectal cancer and advantages of expanded dosing indications.

Biweekly Cetuximab Offers a Convenient Dosing Option in mCRC

July 27th 2021

Richard Kim, MD, discusses the utility of EGFR inhibitors in patients with RAS wild-type colorectal cancer, the convenience of biweekly dosing with cetuximab, recommendations for managing EGFR inhibitor–related treatment-related adverse effects, and novel combinations on the horizon.